

Phytomolecules-drug interactions: clinical and nutritional implications

Phytomolecules from herbal products, as well as bioactive phytochemicals from plant foods and food dressings, have potential health effects [1-4]. However, it is known that herbal products and nutraceuticals could affect drug-metabolizing enzymes and transporters [5, 6].

In susceptible patients, phytomolecules-drug interactions may result in significant therapeutic changes for some drugs with a narrow therapeutic index and there is a growing interest on food-drug interactions. From a search in the MEDLINE database (20/11/2022) with the search terms "food-drug interactions" 2,918 results were retrieved (from 1976 to 2022; 110 case reports from 1995), of which 1,220 in the last ten years.

Moreover, in special populations, such as individuals with a spinal cord injury [3, 4, 7] the evaluation of risk for potential food or nutraceutical interactions with drugs should be monitored also considering the sedentary habit imposed by their condition [7]. Many bioactive compounds have non-linear dose-response effects, acting in the context of the hormetic-based lifestyle medicine [8]. Different health, nutritional, and training status could affect the interactions among phytochemicals and microbiota [8]. The latter is involved in the metabolism of some phytochemicals, such as flavonoids, having low bioavailability and some metabolites can have bioactivities [9]. Therefore, genetic polymorphisms of the detoxification systems, epigenetic mechanisms and differences in gut microbiome could account the inter-individual variability in both efficacy and toxicity [9]. From that,

phytochemicals can act as drugs or pro-drugs and it is difficult to establish a therapeutic index [9, 10].

Moreover, some antioxidants from plant sources have antinutrient effects [11]. Despite the potential adverse effects of high doses of phytomolecules, nutraceuticals are considered safe. In this context was the neglected potential interaction between monacolin K (structurally identical to lovastatin) and some plant foods [12]. From that, the European Commission concluded: "*considering the significant harmful effect on health associated with the use of monacolins from red yeast rice at levels of 10 mg/day, and individual cases of severe adverse health reactions at levels as low as 3 mg/day, the use of monacolins from red yeast rice at levels of 3 mg and more per portion of the product recommended for daily consumption should be prohibited*".

Therefore, the potential risk of interaction between herbal products, dietary supplements and drugs should be evaluated considering the overall lifestyle and nutritional status by using a patient-centered approach.

Dr. Ilaria Peluso

Research Centre for Food and Nutrition, Council for Agricultural Research and Economics, Rome 00178, Italy.

E-mail: ilaria.peluso@crea.gov.it

<https://orcid.org/0000-0002-6210-5241>

References

1. Peluso I, Villano Valencia D, Chen CO; Palmery M. Antioxidant, Anti-Inflammatory, and Microbial-Modulating Activities of



Nutraceuticals and Functional Foods 2019. *Oxid. Med. Cell. Longev.* **2020**, 6981542.

2. Hano C, Peluso I, Chen JT. Editorial: Biomolecules Against Coronaviruses: Molecular Aspects, Multi-Omics and Systems Pharmacology. *Front. Pharmacol.* **2022**, 12;12:835884.

3. Fedullo AL, Ciccotti M, Giannotta P, Alviti F, Bernardi M, Raguzzini A, Toti E, Sciarra T, Peluso I. Hormetic Effects of Bioactive Compounds from Foods, Beverages, and Food Dressing: The Potential Role in Spinal Cord Injury. *Oxid. Med. Cell. Longev.* **2021**, 27;2021:6615752.

4. Raguzzini A, Toti E, Sciarra T, Fedullo AL, Peluso I. Cranberry for Bacteriuria in Individuals with Spinal Cord Injury: A Systematic Review and Meta-Analysis. *Oxid. Med. Cell. Longev.* **2020**, 30;2020:9869851.

5. Gómez-Garduño J, León-Rodríguez R, Alemón-Medina R, Pérez-Guillé BE, Soriano-Rosales RE, González-Ortiz A, Chávez-Pacheco JL, Solorio-López E, Fernandez-Pérez P, Rivera-Espinosa L. Phytochemicals That Interfere With Drug Metabolism and Transport, Modifying Plasma Concentration in Humans and Animals. *Dose Response.* **2022** 21;20(3):15593258221120485.

6. Başaran N, Paslı D, Başaran AA. Unpredictable adverse effects of herbal products. *Food Chem. Toxicol.* **2022** 159:112762.

7. Bernardi M, Fedullo AL, Bernardi E, Munzi D, Peluso I, Myers J, Lista FR, Sciarra T. Diet in neurogenic bowel management: A viewpoint on spinal cord injury. *World J. Gastroenterol.* **2020**, 26(20):2479-2497.

8. Peluso I. Diet and exercise in lifestyle medicine: The hormetic effects of bioactive compounds on human health. *Current Opinion in Toxicology*, **2022**, 30, 100342.

9. Peluso I, Palmery M. Flavonoids at the pharma-nutrition interface: Is a therapeutic index in demand? *Biomed. Pharmacother.*, **2015**, 71:102-7.

10. Peluso I, Palmery M. Editorial: Therapeutic Index for Nutraceuticals in Inflammation-Related Diseases: Efficacy, Bioavailability, Metabolism and Interactions With Drugs, Volume II. *Front. Pharmacol.*, **2022**, 13:868784.

11. Peluso I. Dietary Antioxidants: Micronutrients and Antinutrients in Physiology and Pathology. *Antioxidants (Basel)*. **2019**, 12:642.

12. Raguzzini A, Toti E, Palmery M, Abdel-Daim MM, Peluso I. Dietary Habits and Musculoskeletal Pain in Statin and Red Yeast Rice Users: A Pilot Study. *Eur. J. Investig. Health Psychol. Educ.* **2021**, 11(4):1156-1165.

13. Commission Regulation (EU) 2022/860 of 1 June 2022, amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards monacolins from red yeast rice. <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32022R0860>

Received: 21 November, 2022

Revised: 29 November, 2022

Accepted: 30 November, 2022